Menopur (Menotrophin)

Menotrophin provides exogenous follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). These hormones bind to their specific receptors on ovarian cells, promoting follicle growth, estradiol synthesis, and the LH surge that triggers ovulation, thereby supporting the reproductive cycle.

The dose of Menopur is individualized. A qualified prescriber determines the amount and frequency based on the patient’s ovarian response, hormone levels, body weight, and the specific assisted‑reproduction protocol being followed.

Menopur is not intended for use during an established pregnancy and its safety in pregnancy has not been established. Likewise, there is insufficient data on excretion in breast milk, so breastfeeding is generally not recommended while receiving the product.

To order Menopur, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Menopur contains both FSH and LH activity in a fixed ratio, whereas some alternatives such as recombinant FSH (e.g., follitropin alfa) provide only FSH. The combined activity of Menopur can be advantageous in patients who require both hormones for optimal follicular development, but the choice depends on individual clinical assessment.

Menopur must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Menopur is supplied as a sterile injectable solution. It is administered by a trained healthcare professional either intramuscularly or subcutaneously, typically using a fine‑gauge needle. The injection site and technique are chosen according to the treatment protocol and patient comfort.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can lead to rapid fluid accumulation, thromboembolic events, and, rarely, ovarian cyst rupture or hemorrhage. Prompt monitoring and dose adjustment are essential to mitigate these risks.

Menopur is contraindicated in women with known hypersensitivity to menotrophin or any excipients, in those with active ovarian cysts, uncontrolled thyroid disease, or severe ovarian hyperstimulation syndrome. It should also be avoided in pregnancy and is not recommended for use in patients with certain hormone‑dependent cancers.